Effects of Curcumin-Piperine Supplementation in Fibromyalgia

Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletalpain, fatigue, sleep disturbances, cognitive impairment, and mood disorders. Increasingevidence suggests that its pathogenesis is driven by a complex interaction of centralsensitization, neuroinflammation, and oxidative stress. Elevated levels ofpro‐inflammatory cytokines and oxidative stress biomarkers have been linked to painseverity and disease progression. Although current pharmacological therapies can reducesymptoms, their effectiveness is often limited, and they do not adequately address theunderlying biological mechanisms.In addition to inflammation and oxidative stress, insulin resistance (IR) has recentlyemerged as a potential contributor to fibromyalgia. Several clinical studies havereported higher HOMA‐IR values in patients with FM than in healthy individuals, withgreater insulin resistance being associated with more severe pain and poorer clinicaloutcomes. This relationship may be explained by chronic low‐grade inflammation, increasedoxidative stress, impaired glucose metabolism, and altered central pain processing. Thesefindings suggest that metabolic dysfunction may contribute to symptom persistence andrepresent an additional therapeutic target in FM.Curcumin, a natural polyphenol extracted from "Curcuma longa", has attracted considerableinterest because of its anti‐inflammatory, antioxidant, neuroprotective, and analgesicproperties. In addition to reducing inflammatory mediators, oxidative stress, andmodulating pain pathways, curcumin has been shown to improve insulin sensitivity andglycemic control, suggesting that it may simultaneously target both the inflammatory andmetabolic abnormalities associated with FM.These findings support the hypothesis that curcumin may improve fibromyalgia byaddressing inflammation, oxidative stress, pain sensitization, and metabolic dysfunction.However, current clinical evidence remains limited by small sample sizes and shortintervention periods. Furthermore, curcumin's poor oral bioavailability can be markedlyenhanced by co‐administration with piperine, which increases its intestinal absorption.Therefore, a well‐designed randomized controlled trial is needed to evaluate the efficacyand safety of curcumin‐piperine supplementation as an adjunctive therapy for patientswith fibromyalgia.A total of 80 fibromyalgia patients will be enrolled in the study. Patients will bestratified according to insulin resistance status (insulin‐resistant vs.non‐insulin‐resistant) followed by permuted block randomization to the study groups. Allpatients in both groups will receive standard treatment consisting of duloxetine andgabapentin, along with personalized guidance on an anti‐inflammatory diet and exerciseprogram.Participants will be educated about the study and asked to sign a written informedconsent before starting the study, assuring that they can withdraw at any time if theywant.The following data will be collected from patient records and by history taking from thepatients upon enrollment:A. Patient demographics including age, gender, weight, height, and body mass index (BMI).B. Clinical variables including HbA1c, and HOMA‐IR, complete blood picture, kidneyfunction tests and liver function tests C. Comorbidities including but not limited todiabetes, hypertension, chronic kidney disease, cardiovascular disease, andimmunosuppression.D. Medical history including previous hospitalizations, surgeries, medication history,and known drug allergies.E. Medication history including analgesic consumption (dose, frequency, and duration)The patients will be followed up by weekly phone calls to encourage adherence and toevaluate the incidence and severity of the adverse effects including GIT disturbances orany other undesirable side effects reported by the patients throughout the trial. Inaddition, complete blood picture, kidney function tests, and liver function tests will beassessed at baseline, after 1 month and by the end of the study (after 3 months).